Literature DB >> 31647681

Methods for Accommodating Nonproportional Hazards in Clinical Trials: Ready for the Primary Analysis?

Boris Freidlin1, Edward L Korn1.   

Abstract

Mesh：

Year:  2019        PMID： 31647681      PMCID： PMC7001779          DOI： 10.1200/JCO.19.01681

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  50 in total

1.  Interpreting the Survival Benefit From Neoadjuvant Chemoradiotherapy Before Surgery for Locally Advanced Squamous Cell Carcinoma of the Esophagus.

Authors:  Zachary R McCaw; Lee-Jen Wei
Journal:  J Clin Oncol       Date:  2019-03-06       Impact factor: 44.544

2.  Palbociclib and Fulvestrant in Breast Cancer.

Authors:  Zachary R McCaw; Jason L Vassy; Lee-Jen Wei
Journal:  N Engl J Med       Date:  2019-02-21       Impact factor: 91.245

3.  Trastuzumab Therapy for 9 Weeks vs 1 Year for Human Epidermal Growth Factor 2-Positive Breast Cancer-Reply.

Authors:  Val Gebski; Teppo Huttunen; Heikki Joensuu
Journal:  JAMA Oncol       Date:  2019-01-01       Impact factor: 31.777

4.  Interpreting the Association of First-in-Class Immune Checkpoint Inhibition and Targeted Therapy With Survival in Patients With Stage IV Melanoma.

Authors:  Hajime Uno; Dae Hyun Kim; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

Review 5.  Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.

Authors:  Ludovic Trinquart; Justine Jacot; Sarah C Conner; Raphaël Porcher
Journal:  J Clin Oncol       Date:  2016-02-16       Impact factor: 44.544

6.  Assessing Metronomic Chemotherapy for Progressive Pediatric Solid Malignant Tumors-Reply.

Authors:  Raja Pramanik; Sreenivas Vishnubhatla; Sameer Bakhshi
Journal:  JAMA Oncol       Date:  2018-05-01       Impact factor: 31.777

7.  Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis-Reply.

Authors:  Val Gebski; James Chih-Hsin Yang; Chee Khoon Lee
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777

8.  Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  BMC Med Res Methodol       Date:  2016-02-11       Impact factor: 4.615

9.  End points and statistical considerations in immuno-oncology trials: impact on multiple myeloma.

Authors:  Antje Hoering; Brian Durie; Hongwei Wang; John Crowley
Journal:  Future Oncol       Date:  2017-04-11       Impact factor: 3.404

10.  Estimating and Interpreting the Overall Survival Benefit of Checkpoint Inhibitors via Meta-analysis.

Authors:  Hajime Uno; Lu Tian; Lee-Jen Wei
Journal:  JAMA Oncol       Date:  2018-08-01       Impact factor: 31.777
View more
  9 in total

1.  The Predictive Individual Effect for Survival Data.

Authors:  Beat Neuenschwander; Satrajit Roychoudhury; Simon Wandel; Kannan Natarajan; Emmanuel Zuber
Journal:  Ther Innov Regul Sci       Date:  2022-03-16       Impact factor: 1.778

Review 2.  Quantifying treatment differences in confirmatory trials under non-proportional hazards.

Authors:  José L Jiménez
Journal:  J Appl Stat       Date:  2020-09-03       Impact factor: 1.416

Review 3.  Clinical Benefit Scales and Trial Design: Some Statistical Issues.

Authors:  Edward L Korn; Carmen J Allegra; Boris Freidlin
Journal:  J Natl Cancer Inst       Date:  2022-09-09       Impact factor: 11.816

4.  Pitfall in the Design and Analysis of Comparative Oncology Trials With a Time-to-Event Endpoint and Recommendations.

Authors:  Zachary R McCaw; Dae Hyun Kim; Lee-Jen Wei
Journal:  JNCI Cancer Spectr       Date:  2022-01-05

5.  Are restricted mean survival time methods especially useful for noninferiority trials?

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-02-24       Impact factor: 2.486

6.  Reply to Quartagno et al.

Authors:  Boris Freidlin; Chen Hu; Edward L Korn
Journal:  Clin Trials       Date:  2021-09-15       Impact factor: 2.486

7.  A simulation study comparing the power of nine tests of the treatment effect in randomized controlled trials with a time-to-event outcome.

Authors:  Patrick Royston; Mahesh K B Parmar
Journal:  Trials       Date:  2020-04-06       Impact factor: 2.279

8.  Time-dependent treatment effects of metronomic chemotherapy in unfit AML patients: a secondary analysis of a randomised controlled trial.

Authors:  Phichayut Phinyo; Jayanton Patumanond; Saranya Pongudom
Journal:  BMC Res Notes       Date:  2021-01-06

9.  Assessment of Treatment Effects and Long-term Benefits in Immune Checkpoint Inhibitor Trials Using the Flexible Parametric Cure Model: A Systematic Review.

Authors:  Thomas Filleron; Marine Bachelier; Julien Mazieres; Maurice Pérol; Nicolas Meyer; Elodie Martin; Fanny Mathevet; Jean-Yves Dauxois; Raphael Porcher; Jean-Pierre Delord
Journal:  JAMA Netw Open       Date:  2021-12-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.